Efficacy and safety of dual and triple antiplatelet therapies in East Asian patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized controlled trials
Open Access
- 14 March 2026
- journal article
- review article
- Published by Oxford University Press (OUP) in Postgraduate Medical Journal
Abstract
This systematic review and network meta-analysis (NMA) evaluated the efficacy and safety of dual antiplatelet therapy (DAPT) and triple antiplatelet therapy (TAPT) in East Asian patients with acute coronary syndrome. Twenty-six randomized controlled trials comparing DAPT (P2Y12 inhibitor with aspirin) or TAPT (cilostazol with clopidogrel-based DAPT) were included from four databases. Primary outcomes were major adverse cardiac events (MACEs) and major bleeding events. Frequentist NMA was performed using RRs. The reference comparator was clopidogrel-based DAPT. TAPT significantly reduced MACEs without increasing major bleeding events. Standard-dose potent P2Y12 inhibitor-based DAPT showed no MACE reduction but significantly increased major bleeding events. TAPT had the highest probability of reducing MACEs, while DAPT incorporating potent P2Y12 inhibitors with de-escalation had the highest probability of minimizing major bleeding events. To conclude, TAPT demonstrates promising efficacy without compromising safety, while de-escalation strategies appear effective in balancing the efficacy and safety of DAPT.Keywords
This publication has 43 references indexed in Scilit:
- Efficacy and safety of cilostazol-based triple antiplatelet therapy compared with clopidogrel-based dual antiplatelet therapy in patients with acute ST-elevation myocardial infarction undergoing percutaneous coronary intervention: A multicenter, randomized, open-label, phase 4 trialAmerican Heart Journal, 2023
- Comparison of Clopidogrel Monotherapy After 1 to 2 Months of Dual Antiplatelet Therapy With 12 Months of Dual Antiplatelet Therapy in Patients With Acute Coronary SyndromeJAMA Cardiology, 2022
- Update on Cilostazol: A Critical Review of Its Antithrombotic and Cardiovascular Actions and Its Clinical ApplicationsThe Journal of Clinical Pharmacology, 2021
- Safety and feasibility of low‐dose ticagrelor in patients with ST‐segment elevation myocardial infarctionClinical Cardiology, 2020
- Effect of Ticagrelor Monotherapy vs Ticagrelor With Aspirin on Major Bleeding and Cardiovascular Events in Patients With Acute Coronary SyndromeJAMA, 2020
- MetaInsight: An interactive web‐based tool for analyzing, interrogating, and visualizing network meta‐analyses using R‐shiny and netmetaResearch Synthesis Methods, 2019
- Comparison of 1-Year Outcomes of Triple (Aspirin + Clopidogrel + Cilostazol) Versus Dual Antiplatelet Therapy (Aspirin + Clopidogrel + Placebo) After Implantation of Second-Generation Drug-Eluting Stents into One or More Coronary Arteries: from the DECREASE-PCI TrialThe American Journal of Cardiology, 2018
- Network meta-analysis: an introduction for cliniciansInternal and Emergency Medicine, 2016
- Cilostazol reduces the progression of carotid intima-media thickness without increasing the risk of bleeding in patients with acute coronary syndrome during a 2-year follow-upHeart and Vessels, 2010
- Cilostazol in addition to aspirin and clopidogrel improves long-term outcomes after percutaneous coronary intervention in patients with acute coronary syndromes: A randomized, controlled studyAmerican Heart Journal, 2009